List of Gene Editing/CRISPR Companies in United Kingdom - 18

4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.

Driven by innovative science and our entrepreneurial culture, we are focused on the delivery of life-changing medicines that are fuelling growth and contributing value to patients and society.

World leaders in iPSC technology supporting the next generation of advanced models for drug discovery We provide biopharma and virtual organizations with human iPSC-derived cells and outsourced laboratory services to support drug discovery in the neurodegenerative, neuroinflammatory, and cardiotoxicity areas. As leaders in human induced pluripotent stem cell (iPSC) products and services, we support the pursuit of more human-relevant in vitro models to develop better, safer therapies. We have over a decade of experience supplying top ten Biopharma institutions and drug discovery companies with robust, high-quality in vitro models and custom lab services. Our industry-leading iPSC capabilities support the pursuit of advanced in vitro disease models and supply volume for organ-on-a-chip devices and microfluidics platforms. From simple monoculture models to complex co- and tri-culture and 3D models, we continue to pioneer the advanced utility of iPSCs for research and drug discovery.

At Biofortuna we form unique partnerships with the most innovative healthcare and life science companies and work together to enhance health and wellbeing all over the world. Our services are wide-ranging, and whether we are supporting diagnostic companies, food safety experts or life science specialists our objectives are the same; to form long term partnerships and become a valued extension of your team. We do that by solving problems and presenting opportunities. We listen to your requirements, develop customised solutions and deliver them with openness and transparency. Operating from state-of-the art, purpose built premises, and benefiting from ISO 13485 certification, ISO 17025 accreditation and FDA registration, we have a proven track record in the development and large-scale manufacture of PCR and LAMP molecular assays and immunoassays.

Broken String Bioscience’s technology platform, INDUCE-seq™, supports the development of cell and gene therapies that are safer by design. INDUCE-seq™, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs

Genus is a world-leading animal genetics company. At the forefront of innovation in gene-editing, advanced reproductive biology, and other breakthrough breeding technologies, Genus R&D advances an agricultural practice thousands of years old – animal breeding. Our goal is to ensure the global food system continues to nurture healthy, productive animals that yield affordable, high-quality proteins for a sustainable future. We believe a more sustainable food system starts with better breeding and genetics. Through ABS Global (bovine) and PIC (porcine), we supply high-quality breeding animals with desirable characteristics to farmers, enabling them to produce better quality meat and milk more efficiently to feed the world more sustainably. Our breeding animals’ desirable characteristics include feed efficiency, disease resistance, growth rate, protein and fat content, and fertility. ABS Global is the world-leading provider of bovine genetics, reproduction services, technologies, and udder care products. Marketing in more than 70 countries around the globe, ABS has been at the forefront of animal genetics and technology since its founding in 1941. In bovine genetics, ABS serves more than 40,000 customers globally, including some of the world’s leading beef and dairy producers. PIC, which stands for ‘Pig Improvement Company,’ was founded in 1962 in Oxfordshire, England. PIC strives to make their customers the most successful pig producers in the world and their “Never Stop Improving” philosophy means a continuous effort to listen carefully to customers and drive innovation to create ever-increasing value for pig and pork producers.

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Intima Bioscience - A clinical stage gene and cell therapy company focused on curative intent in solid tumor cancer

Based in Edinburgh, Scotland. Lentitek has pioneered the development of alternative approaches to lentiviral vector production based on novel promoter technology conceived by Dr Adam Inche. The Lentitek platform was developed to address key issues limiting progression of ATMP assets and is now enabling the use of retrovirus based vectors in new and previously unviable applications. Unique properties of the Lentitek platform can be leveraged to enable in-vivo CAR-T and armoured CAR applications in addition to addressing quality and yield inconsistencies within ex-vivo CAR-T manufacture. The Lentitek platform is accessed through a serviced CRO license model where Lentiteks’ renowned team of vector design specialists work with asset developers to integrate the Ltek solution and validate performance including transfer to chosen manufacturing partner.

Macomics is a biotechnology company that focuses on developing precision medicines to modulate macrophages for the treatment of cancer.

Mootral is a British biotech company operating at the intersection of two existential crises of our time - climate change and antimicrobial resistance. Our natural solutions are enabling a shift to new standards in agriculture by allowing farmers and processors to significantly reduce their methane footprint and improve animal health, thereby future-proofing our global food ecosystem. mootral.com

Oxford Genetics is a synthetic biology company focused on developing novel technologies to overcome challenges associated with the discovery, development and production of biologics, gene therapies, cell therapies and vaccines.

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines. Roquefort Therapeutics’ portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of: 1. Midkine antibodies with significant in vivo efficacy and toxicology studies; 2. Midkine RNA therapeutics with novel anti-cancer gene editing action; 3. MK cell therapy with direct and NK-mediated anti-cancer action; and 4. siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.

RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones, including being among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR-edited stem cell-based therapy for a major disease to marketing authorization. Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide. Discover more about our services at www.roslinct.com.

Sense is transforming healthcare by redefining diagnostics. Founded in 2014, we strive to improve lives by bringing powerful tools for fast, accurate, and accessible diagnostics to all. We’re focused on creating a portfolio of unconstrained, instrument-free molecular diagnostic technologies. Our Veros™ platform introduces novel and proprietary rapid molecular amplification technology to detect a variety of deadly and costly diseases. We’re developing technologies that combine the power of laboratory tests with the simplicity and ease of use of products because we believe that if you can test anywhere, you can change everything.* *Professional use, patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations.

Tropic Biosciences develops high-performing commercial varieties of tropical crops whichpromote grower well being, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques. Some of the products being developed are disease resistant bananas and caffiene-free coffee.